{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:44:25Z","timestamp":1775601865219,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"takeda pharmaceutical company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with type 2 diabetes (T2D) may experience frequent body weight changes over time. The prognostic impact of these weight changes (gains or losses) requires further study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To study the associations between changes in body weight (intentional or unintentional) with subsequent outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The EXAMINE trial included 5380 patients with T2D and a recent acute coronary syndrome, who were randomized to alogliptin or placebo. Time-updated Cox models and mixed effects models were used to test the associations between changes in body weight and subsequent outcomes over a median follow-up of 1.6 (1.0\u20132.1) years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the post-randomization follow-up period, 1044 patients (19.4%) experienced a weight loss\u2009\u2265\u20095% of baseline weight, 2677 (49.8%) had a stable weight, and 1659 (30.8%) had a\u2009\u2265\u20095\u2009% weight gain. Patients with weight loss were more frequently women and had more co-morbid conditions. In contrast, patients who gained\u2009\u2265\u20095% weight were more frequently men with less co-morbid conditions. A weight loss\u2009\u2265\u20095% was independently associated with a higher risk of subsequent adverse outcomes, including all-cause mortality: adjusted HR (95% CI)\u2009=\u20091.79 (1.33\u20132.42), P\u2009&lt;\u20090.001. Similar associations were found for cardiovascular mortality, the composite of cardiovascular mortality or heart failure hospitalization, and the primary outcome. A weight gain\u2009\u2265\u20095% was independently associated with an increase in the risk of subsequent cardiovascular mortality or heart failure hospitalization only: adjusted HR (95% CI)\u2009=\u20091.34 (1.02\u20131.76), P\u2009=\u20090.033.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with T2D who had a recent ACS\/MI, a\u2009\u2265\u20095% loss of body weight was associated with a higher risk of subsequent cardiovascular events and mortality.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-021-01382-8","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T14:03:05Z","timestamp":1631628185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[]},{"given":"Cyrus","family":"Mehta","sequence":"additional","affiliation":[]},{"given":"William B.","family":"White","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"issue":"6","key":"1382_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00592-018-1126-y","volume":"55","author":"R Salehidoost","year":"2018","unstructured":"Salehidoost R, Mansouri A, Amini M, Yamini SA, Aminorroaya A. Body mass index and the all-cause mortality rate in patients with type 2 diabetes mellitus. Acta Diabetol. 2018;55(6):569\u201377. https:\/\/doi.org\/10.1007\/s00592-018-1126-y.","journal-title":"Acta Diabetol"},{"issue":"28","key":"1382_CR2","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/eurheartj\/ehaa293","volume":"21","author":"W Doehner","year":"2020","unstructured":"Doehner W, Gerstein HC, Ried J, et al. Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. Eur Heart J. 2020;21(28):2668\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa293.","journal-title":"Eur Heart J"},{"issue":"6","key":"1382_CR3","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.2337\/dc06-2544","volume":"30","author":"KM Narayan","year":"2007","unstructured":"Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007;30(6):1562\u20136. https:\/\/doi.org\/10.2337\/dc06-2544.","journal-title":"Diabetes Care"},{"issue":"9669","key":"1382_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/s0140-6736(09)60318-4","volume":"28","author":"G Whitlock","year":"2009","unstructured":"Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;28(9669):1083\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(09)60318-4.","journal-title":"Lancet"},{"issue":"23","key":"1382_CR5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1000367","volume":"2","author":"A Berrington de Gonzalez","year":"2010","unstructured":"Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;2(23):2211\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1000367.","journal-title":"N Engl J Med"},{"issue":"11","key":"1382_CR6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00392-019-01453-7","volume":"108","author":"S Stienen","year":"2019","unstructured":"Stienen S, Ferreira JP, Girerd N, et al. Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and\/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. Clin Res Cardiol. 2019;108(11):1215\u201325. https:\/\/doi.org\/10.1007\/s00392-019-01453-7.","journal-title":"Clin Res Cardiol"},{"issue":"9","key":"1382_CR7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.7326\/m14-1551","volume":"5","author":"P Costanzo","year":"2015","unstructured":"Costanzo P, Cleland JG, Pellicori P, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Intern Med. 2015;5(9):610\u20138. https:\/\/doi.org\/10.7326\/m14-1551.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1382_CR8","doi-asserted-by":"publisher","first-page":"e0146889","DOI":"10.1371\/journal.pone.0146889","volume":"11","author":"R K\u00f8ster-Rasmussen","year":"2016","unstructured":"K\u00f8ster-Rasmussen R, Simonsen MK, Siersma V, Henriksen JE, Heitmann BL, de Fine Olivarius N. Intentional weight loss and longevity in overweight patients with type 2 diabetes: a population-based cohort study. PLoS ONE. 2016;11(1):e0146889. https:\/\/doi.org\/10.1371\/journal.pone.0146889.","journal-title":"PLoS ONE"},{"issue":"2","key":"1382_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"11","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;11(2):145\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1212914.","journal-title":"N Engl J Med"},{"issue":"4","key":"1382_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","volume":"162","author":"WB White","year":"2011","unstructured":"White WB, Bakris GL, Bergenstal RM, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162(4):620\u20131. https:\/\/doi.org\/10.1016\/j.ahj.2011.08.004.","journal-title":"Am Heart J"},{"issue":"14","key":"1382_CR11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"3","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;3(14):1327\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1305889.","journal-title":"N Engl J Med"},{"key":"1382_CR12","doi-asserted-by":"publisher","unstructured":"Ferreira JP, Sharma A, Mehta C, et al. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol\u00a02020.\u00a0https:\/\/doi.org\/10.1007\/s00392-020-01729-3.","DOI":"10.1007\/s00392-020-01729-3"},{"key":"1382_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ahj.2020.07.014","volume":"6","author":"M Elharram","year":"2020","unstructured":"Elharram M, Sharma A, White W, et al. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020;6:40\u201351. https:\/\/doi.org\/10.1016\/j.ahj.2020.07.014.","journal-title":"Am Heart J"},{"issue":"7","key":"1382_CR14","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/dom.14371","volume":"23","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Lamiral Z, Bakris G, Mehta C, White WB, Zannad F. Red cell distribution width in patients with diabetes and myocardial infarction: an analysis from the EXAMINE trial. Diabetes Obes Metab. 2021;23(7):1580\u20137. https:\/\/doi.org\/10.1111\/dom.14371.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1382_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ejhf.240","volume":"17","author":"P Rossignol","year":"2015","unstructured":"Rossignol P, Masson S, Barlera S, et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail. 2015;17(4):424\u201333. https:\/\/doi.org\/10.1002\/ejhf.240.","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"1382_CR16","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/eurheartj\/ehn420","volume":"29","author":"SJ Pocock","year":"2008","unstructured":"Pocock SJ, McMurray JJ, Dobson J, et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(21):2641\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehn420.","journal-title":"Eur Heart J"},{"issue":"3","key":"1382_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","volume":"63","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793\u2013808. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00803.x.","journal-title":"Kidney Int"},{"issue":"1","key":"1382_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12933-020-01170-w","volume":"10","author":"SJ Park","year":"2020","unstructured":"Park SJ, Ha KH, Kim DJ. Body mass index and cardiovascular outcomes in patients with acute coronary syndrome by diabetes status: the obesity paradox in a Korean national cohort study. Cardiovasc Diabetol. 2020;10(1):191. https:\/\/doi.org\/10.1186\/s12933-020-01170-w.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1382_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12933-019-0934-x","volume":"1","author":"LR Pedersen","year":"2019","unstructured":"Pedersen LR, Olsen RH, Anholm C, et al. Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial. Cardiovasc Diabetol. 2019;1(1):127. https:\/\/doi.org\/10.1186\/s12933-019-0934-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1382_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12933-021-01285-8","volume":"30","author":"YH Chan","year":"2021","unstructured":"Chan YH, Chen SW, Chao TF, Kao YW, Huang CY, Chu PH. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor. Cardiovasc Diabetol. 2021;30(1):93. https:\/\/doi.org\/10.1186\/s12933-021-01285-8.","journal-title":"Cardiovasc Diabetol"},{"issue":"9901","key":"1382_CR21","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/s0140-6736(13)61249-0","volume":"19","author":"FG Fowkes","year":"2013","unstructured":"Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;19(9901):1329\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(13)61249-0.","journal-title":"Lancet"},{"issue":"8","key":"1382_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","volume":"27","author":"A Wang","year":"2019","unstructured":"Wang A, Green JB, Halperin JL, Piccini JP. Sr. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;27(8):1107\u201315. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.020.","journal-title":"J Am Coll Cardiol"},{"issue":"9888","key":"1382_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/s0140-6736(13)60687-x","volume":"20","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;20(9888):260\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(13)60687-x.","journal-title":"Lancet"},{"issue":"3","key":"1382_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1523-1755.2004.00863.x","volume":"66","author":"A Mohanram","year":"2004","unstructured":"Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004;66(3):1131\u20138. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00863.x.","journal-title":"Kidney Int"},{"issue":"4","key":"1382_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1161\/circheartfailure.114.001957","volume":"8","author":"A Lala","year":"2015","unstructured":"Lala A, McNulty SE, Mentz RJ, et al. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail. 2015;8(4):741\u20138. https:\/\/doi.org\/10.1161\/circheartfailure.114.001957.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"1382_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12933-021-01326-2","volume":"12","author":"SS Moazzeni","year":"2021","unstructured":"Moazzeni SS, Hizomi Arani R, Deravi N, et al. Weight change and risk of cardiovascular disease among adults with type 2 diabetes: more than 14 years of follow-up in the Tehran Lipid and Glucose Study. Cardiovasc Diabetol. 2021;12(1):141. https:\/\/doi.org\/10.1186\/s12933-021-01326-2.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01382-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T02:02:38Z","timestamp":1631671358000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01382-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01382-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"28 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board approval was obtained, ethics approval was obtained at each participating site, and all patients provided informed consent to participate in the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Ferreira is a consultant for Boehringer-Ingelheim, and receives research support from AstraZeneca and Novartis. Dr. Rossignol reports personal fees from Ablative Solutions, AstraZeneca, Bayer, Boehringer-Ingelheim, Corvidia, CVRx, Fresenius, G3P (stocks), Grunenthal, Idorsia, KBP, Novartis, NovoNordisk, Relypsa, Sanofi, Sequana Medical, Servier, Stealth Peptides, Vifor, Vifor Fresenius Medical Care Renal Pharma; and Cofounder: CardioRenal, a company developing sensors for the home monitoring of potassium and creatinine. Dr. Zannad reports personal fees from Boehringer Ingelheim during the conduct of the study; personal fees from Janssen, Novartis, Boston Scientific, Amgen, CVRx, AstraZeneca, Vifor Fresenius, Cardior, Cereno pharmacuetical, Applied Therapeutics, Merck, Bayer, and Cellprothera outside the submitted work; and other support from CVCT and Cardiorenal, outside the submitted work. Dr. Bakris, has received personal fees from Takeda Development Center, is a consultant for Merck, Relypsa, and is on the steering committee for international renal\/CV outcomes trials for Janssen, Bayer, Vascular Dynamics. Dr. White has received research support from the National Institute of Aging (NIH) and personal fees from Takeda Development Center (Deerfield, IL, USA) during the conduct of the EXAMINE trial until 2016 (Steering Committee Chair). All the other authors reported not having potential conflicts of interest relevant to this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}